{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:03:55Z","timestamp":1789790635471,"version":"4.0.1"},"reference-count":42,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,9,18]]},"DOI":"10.1248\/bpb.b26-00273","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:12:04Z","timestamp":1789683124000},"page":"1538-1549","source":"Crossref","is-referenced-by-count":0,"title":["Saikosaponin D Ameliorates Non-alcoholic Steatohepatitis by Inhibiting STING-Mediated Macrophage M1 Polarization in Mice"],"prefix":"10.1248","volume":"49","author":[{"given":"Wenjie","family":"Zhang","sequence":"first","affiliation":[{"name":"Tianjin Nankai Hospital, Tianjin Medical University, Tianjin 300100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yin","sequence":"first","affiliation":[{"name":"Hospital of Integrated Chinese and Western Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Cheng","sequence":"additional","affiliation":[{"name":"Hospital of Integrated Chinese and Western Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Nankai Hospital, Tianjin Medical University, Tianjin 300100, China"},{"name":"Tianjin Key Laboratory of Acute Abdomen Disease Associated Organ Injury and ITCWM Repair, Tianjin 300100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Cui","sequence":"additional","affiliation":[{"name":"Tianjin Nankai Hospital, Tianjin Medical University, Tianjin 300100, China"},{"name":"Tianjin Key Laboratory of Acute Abdomen Disease Associated Organ Injury and ITCWM Repair, Tianjin 300100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Hospital of Integrated Chinese and Western Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300100, China"},{"name":"Tianjin Key Laboratory of Acute Abdomen Disease Associated Organ Injury and ITCWM Repair, Tianjin 300100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. <i>Hepatology<\/i>, <b>77<\/b>, 1335\u20131347 (2023).","DOI":"10.1097\/HEP.0000000000000004"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Wang Y, Li L, Chen L, Xia J, Wang T, Han L, Cao L, Wang Z, Xiao W, Jiang S. The influence of emodin succinyl ethyl ester on non-alcoholic steatohepatitis induced by a diet high in fructose, cholesterol, and fat in mice. <i>Biol. Pharm. Bull.<\/i>, <b>47<\/b>, 978\u2013987 (2024).","DOI":"10.1248\/bpb.b23-00903"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Tacke F, Puengel T, Loomba R, Friedman SL. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. <i>J. Hepatol.<\/i>, <b>79<\/b>, 552\u2013566 (2023).","DOI":"10.1016\/j.jhep.2023.03.038"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Park SJ, Garcia Diaz J, Um E, Hahn YS. Major roles of kupffer cells and macrophages in NAFLD development. <i>Front. Endocrinol.<\/i>, <b>14<\/b>, 1150118 (2023).","DOI":"10.3389\/fendo.2023.1150118"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Wen Y, Lambrecht J, Ju C, Tacke F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. <i>Cell. Mol. Immunol.<\/i>, <b>18<\/b>, 45\u201356 (2021).","DOI":"10.1038\/s41423-020-00558-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. <i>Nat. Rev. Gastroenterol. Hepatol.<\/i>, <b>14<\/b>, 397\u2013411 (2017).","DOI":"10.1038\/nrgastro.2017.38"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. <i>J. Pathol.<\/i>, <b>229<\/b>, 176\u2013185 (2013).","DOI":"10.1002\/path.4133"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Gong J, Gao X, Ge S, Li H, Wang R, Zhao L. The Role of cGAS-STING signalling in metabolic diseases: from signalling networks to targeted intervention. <i>Int. J. Biol. Sci.<\/i>, <b>20<\/b>, 152\u2013174 (2024).","DOI":"10.7150\/ijbs.84890"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Decout A, Katz JD, Venkatraman S, Ablasser A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. <i>Nat. Rev. Immunol.<\/i>, <b>21<\/b>, 548\u2013569 (2021).","DOI":"10.1038\/s41577-021-00524-z"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Wang X, Rao H, Zhao J, Wee A, Li X, Fei R, Huang R, Wu C, Liu F, Wei L. STING expression in monocyte-derived macrophages is associated with the progression of liver inflammation and fibrosis in patients with nonalcoholic fatty liver disease. <i>Lab. Invest.<\/i>, <b>100<\/b>, 542\u2013552 (2020).","DOI":"10.1038\/s41374-019-0342-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Yu Y, Liu Y, An W, Song J, Zhang Y, Zhao X. STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis. <i>J. Clin. Invest.<\/i>, <b>129<\/b>, 546\u2013555 (2019).","DOI":"10.1172\/JCI121842"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Luo X, Li H, Ma L, <i>et al<\/i>. Expression of STING is increased in liver tissues from patients with NAFLD and promotes macrophage-mediated hepatic inflammation and fibrosis in mice. <i>Gastroenterology<\/i>, <b>155<\/b>, 1971\u201384.e4 (2018).","DOI":"10.1053\/j.gastro.2018.09.010"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Guo X, Yin X, Liu Z, Wang J. Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. <i>Int. J. Mol. Sci.<\/i>, <b>23<\/b>, 15489 (2022).","DOI":"10.3390\/ijms232415489"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Xu Y, Yang C, Zhang S, Li J, Xiao Q, Huang W. Ginsenoside Rg1 protects against non-alcoholic fatty liver disease by ameliorating lipid peroxidation, endoplasmic reticulum stress, and inflammasome activation. <i>Biol. Pharm. Bull.<\/i>, <b>41<\/b>, 1638\u20131644 (2018).","DOI":"10.1248\/bpb.b18-00132"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Zhu S, Hao D, Mao B, Hua Y, Wang B, Wang P, Yuan W. The Dual role of saikosaponins in liver disease treatment: a comprehensive review of pharmacological activities and toxicological characteristics. <i>Biol. Pharm. Bull.<\/i>, <b>49<\/b>, 759\u2013769 (2026).","DOI":"10.1248\/bpb.b25-00787"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ashour ML, Wink M. Genus <i>Bupleurum<\/i>: a review of its phytochemistry, pharmacology and modes of action. <i>J. Pharm. Pharmacol.<\/i>, <b>63<\/b>, 305\u2013321 (2011).","DOI":"10.1111\/j.2042-7158.2010.01170.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Zhu Y, Lai Y. Pharmacological properties and derivatives of saikosaponins-a review of recent studies. <i>J. Pharm. Pharmacol.<\/i>, <b>75<\/b>, 898\u2013909 (2023).","DOI":"10.1093\/jpp\/rgad052"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Yang Y, Chen H, Sun J, Chen Y, Bai D, Wang S, Zhang J, Song J, Sun Z, Dai L. Research progress on extraction, purification, biotransformation, pharmacological effects, toxicity, combined therapy and new dosage forms of saikosaponins. <i>J. Ethnopharmacol.<\/i>, <b>352<\/b>, 120274 (2025).","DOI":"10.1016\/j.jep.2025.120274"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Li X, Ge J, Li Y, Cai Y, Zheng Q, Huang N, Gu Y, Han Q, Li Y, Sun R, Liu R. Integrative lipidomic and transcriptomic study unravels the therapeutic effects of saikosaponins A and D on non-alcoholic fatty liver disease. <i>Acta Pharm. Sin. B<\/i>, <b>11<\/b>, 3527\u20133541 (2021).","DOI":"10.1016\/j.apsb.2021.03.018"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Li X, Li X, Huang N, Liu R, Sun R. A comprehensive review and perspectives on pharmacology and toxicology of saikosaponins. <i>Phytomedicine<\/i>, <b>50<\/b>, 73\u201387 (2018).","DOI":"10.1016\/j.phymed.2018.09.174"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Cherrington NJ. Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models. <i>Drug Metab. Dispos.<\/i>, <b>42<\/b>, 586\u2013595 (2014).","DOI":"10.1124\/dmd.113.055996"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Jung IR, Ahima RS, Kim SF. Time-restricted feeding ameliorates methionine-choline deficient diet-induced steatohepatitis in mice. <i>Int. J. Mol. Sci.<\/i>, <b>25<\/b>, 1390 (2024).","DOI":"10.3390\/ijms25031390"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Miguel FM, Picada JN, da Silva JB, Schemitt EG, Colares JR, Hartmann RM, Marroni CA, Marroni NP. Melatonin attenuates inflammation, oxidative stress, and DNA damage in mice with nonalcoholic steatohepatitis induced by a methionine- and choline-deficient diet. <i>Inflammation<\/i>, <b>45<\/b>, 1968\u20131984 (2022).","DOI":"10.1007\/s10753-022-01667-4"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Luo W, Xu G, Song Z, Mu W, Wen J, Hui S, Zhao J, Zhan X, Bai Z, Xiao X. Licorice extract inhibits the cGAS-STING pathway and protects against non-alcoholic steatohepatitis. <i>Front. Pharmacol.<\/i>, <b>14<\/b>, 1160445 (2023).","DOI":"10.3389\/fphar.2023.1160445"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Gu Y, Duan S, Ding M, Zheng Q, Fan G, Li X, Li Y, Liu C, Sun R, Liu R. Saikosaponin D attenuates metabolic associated fatty liver disease by coordinately tuning PPAR\u03b1 and INSIG\/SREBP1c pathway. <i>Phytomedicine<\/i>, <b>103<\/b>, 154219 (2022).","DOI":"10.1016\/j.phymed.2022.154219"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Haag SM, Gulen MF, Reymond L, Gibelin A, Abrami L, Decout A, Heymann M, van der Goot FG, Turcatti G, Behrendt R, Ablasser A. Targeting STING with covalent small-molecule inhibitors. <i>Nature<\/i>, <b>559<\/b>, 269\u2013273 (2018).","DOI":"10.1038\/s41586-018-0287-8"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Du P, Xu J, Jiang Y, Zhao J, Gao C, Fang Y, Yang X, Yang YP, Zhang JA. Saikosaponin-d attenuates Hashimoto\u2019s thyroiditis by regulating macrophage polarization. <i>J. Immunol. Res.<\/i>, <b>2022<\/b>, 7455494 (2022).","DOI":"10.1155\/2022\/7455494"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Ding J, Sun A, Hu H, Li J, Lu S, Song J, He J, Song X, Qian S, Tian Z. Potential targets and mechanisms of saikosaponin D in psoriasis: a bioinformatic and experimental study on oxidative stress. <i>J. Inflamm. Res.<\/i>, <b>18<\/b>, 16487\u201316507 (2025).","DOI":"10.2147\/JIR.S563272"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Gao T, Wang T, Wu L, Tong Y, Tian J, Zhao K, Wang H. Saikosaponin-d alleviates depression by promoting NLRP3 ubiquitination and inhibiting inflammasome activation. <i>Int. Immunopharmacol.<\/i>, <b>127<\/b>, 111324 (2024).","DOI":"10.1016\/j.intimp.2023.111324"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Xu X, Cui L, Zhang L, Yang L, Zhuo Y, Li C. Saikosaponin d modulates the polarization of tumor-associated macrophages by deactivating the PI3K\/AKT\/mTOR pathway in murine models of pancreatic cancer. <i>Int. Immunopharmacol.<\/i>, <b>122<\/b>, 110579 (2023).","DOI":"10.1016\/j.intimp.2023.110579"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Han Y, Ling Q, Wu L, Wang X, Wang Z, Chen J, Zheng Z, Zhou Z, Jia L, Li L, Wang B. <i>Akkermansia muciniphila<\/i> inhibits nonalcoholic steatohepatitis by orchestrating TLR2-activated \u03b3\u03b4T17 cell and macrophage polarization. <i>Gut Microbes<\/i>, <b>15<\/b>, 2221485 (2023).","DOI":"10.1080\/19490976.2023.2221485"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Wang C, Ma C, Gong L, Guo Y, Fu K, Zhang Y, Zhou H, Li Y. Macrophage polarization and its role in liver disease. <i>Front. Immunol.<\/i>, <b>12<\/b>, 803037 (2021).","DOI":"10.3389\/fimmu.2021.803037"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Ganguly S, Rosenthal SB, Ishizuka K, Troutman TD, Rohm TV, Khader N, Aleman-Muench G, Sano Y, Archilei S, Soroosh P, Olefsky JM, Feldstein AE, Kisseleva T, Loomba R, Glass CK, Brenner DA, Dhar D. Lipid-associated macrophages\u2019 promotion of fibrosis resolution during MASH regression requires TREM2. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>121<\/b>, e2405746121 (2024).","DOI":"10.1073\/pnas.2405746121"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Geng Y, Faber KN, de Meijer VE, Blokzijl H, Moshage H. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? <i>Hepatol. Int.<\/i>, <b>15<\/b>, 21\u201335 (2021).","DOI":"10.1007\/s12072-020-10121-2"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Garcia-Martinez I, Santoro N, Chen Y, Hoque R, Ouyang X, Caprio S, Shlomchik MJ, Coffman RL, Candia A, Mehal WZ. Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9. <i>J. Clin. Invest.<\/i>, <b>126<\/b>, 859\u2013864 (2016).","DOI":"10.1172\/JCI83885"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Chen C, Yang RX, Xu HG. STING and liver disease. <i>J. Gastroenterol.<\/i>, <b>56<\/b>, 704\u2013712 (2021).","DOI":"10.1007\/s00535-021-01803-1"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Zhi H, Fu H, Zhang Y, Fan N, Zhao C, Li Y, Sun Y, Li Y. Progress of cGAS-STING signaling pathway-based modulation of immune response by traditional Chinese medicine in clinical diseases. <i>Front. Immunol.<\/i>, <b>15<\/b>, 1510628 (2024).","DOI":"10.3389\/fimmu.2024.1510628"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Yang T, Qu X, Zhao J, Wang X, Wang Q, Dai J, Zhu C, Li J, Jiang L. Macrophage PTEN controls STING-induced inflammation and necroptosis through NICD\/NRF2 signaling in APAP-induced liver injury. <i>Cell Commun. Signal.<\/i>, <b>21<\/b>, 160 (2023).","DOI":"10.1186\/s12964-023-01175-4"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Zhang Z, Zhou H, Ouyang X, Dong Y, Sarapultsev A, Luo S, Hu D. Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy. <i>Signal Transduct. Target. Ther.<\/i>, <b>7<\/b>, 394 (2022).","DOI":"10.1038\/s41392-022-01252-z"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Zhang F, Chen L, Jin H, Shao J, Wu L, Lu Y, Zheng S. Activation of Fas death receptor pathway and Bid in hepatocytes is involved in saikosaponin D induction of hepatotoxicity. <i>Environ. Toxicol. Pharmacol.<\/i>, <b>41<\/b>, 8\u201313 (2016).","DOI":"10.1016\/j.etap.2015.11.005"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Chua D, Low ZS, Cheam GX, Ng AS, Tan NS. Utility of human relevant preclinical animal models in navigating NAFLD to MAFLD paradigm. <i>Int. J. Mol. Sci.<\/i>, <b>23<\/b>, 14762 (2022).","DOI":"10.3390\/ijms232314762"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Arumugam S, Li B, Boodapati SLT, Nathanson MH, Sun B, Ouyang X, Mehal WZ. Mitochondrial DNA and the STING pathway are required for hepatic stellate cell activation. <i>Hepatology<\/i>, <b>78<\/b>, 1448\u20131461 (2023).","DOI":"10.1097\/HEP.0000000000000388"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00273\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:27:52Z","timestamp":1789788472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00273\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00273","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"b26-00273"}}